The latest clinical data on FAPILAVe therapeutics COVID-19! Recommended for general patients preferred treatment.

Favipiravir, a bird-based similarion approved for flu treatment, has previously been shown to be effective in suppressing RNA-dependent RNA polymerase for a range of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, Novak virus and enteroviruses.
a study published in Cell Research on February 4 this year showed that Fabilavhas has the activity of fighting the new coronavirus (SARS-CoV-2) in vitro.
currently, the drug is expected to treat COVID-19, and a number of clinical trials are under way.
Source: China Clinical Trial Stakes Last week, the registration number ChiCTR2000029600 was the first to announce the results.
study, 35 patients with normal TYPE COVID-19 were treated with Fabilavi, and 45 COVID-19 patients in the control group were treated with lopinavir/litonevir tablets.
results showed that the median time for virus removal in the Fapilavir treatment group was shorter, with a median of 4 days (2.5-9 days), compared with 11 days (8-13 days) in the control group, with significant differences between the two groups.
, the Fapilavir treatment group had fewer adverse reactions and better tolerance than the control group.
Source: MedRxiv On March 20, researchers from Wuhan University Zhongnan Hospital and other institutions announced the results of another clinical trial with the registration number ChiCTR200030254 on the preprinted platform medRxiv.
the trial was designed to assess the effectiveness and safety of Fapilavir's treatment of adult COVID-19 patients compared to Abidor (recommended for antiviral therapy in the new Coronavirus Pneumonia Clinic (Trial Version 6).
Knowledge Card: Abidoor is a broad-spectrum antiviral drug, mainly to treat A, B influenza virus and other caused by upper respiratory tract infections, previous studies have shown that SARS-CoV and MERS-CoV coronavirus have a certain inhibitory activity.
According to the results of the team of Academician Li Lanxuan, Abidoor, compared with the drug's untreated control group at concentration of 10 to 30 micromoles, can effectively suppress coronavirus to 60 times, and significantly inhibit the lesions effect of the virus on cells.
specifically, the study recruited 240 patients, and 120 patients randomly assigned to the trial group received routine treatment , with fapilavir treatment (1600 mg/times a day, 2 times a day; 600 mg/times a day from day 2 to the end of the trial;
both groups had a course of treatment of 7-10 days (if necessary, the duration of treatment could be extended to 10 days, according to the researchers).
other drugs, in addition to Abidor and Fabiravir, are used in routine and treatment to improve adverse reactions.
basic characteristics of the participants Source: MedRxiv Study showed that in the FAS queue, the 7-day clinical recovery rate for patients with normal COVID-19 was 55.86 percent, while the corresponding data for the Fapilave group (a total of 116 patients can be assessed) were 71.43 percent (P-0.0199) (table below).
source: medRxiv for patients with general type COVID-19 and COVID-19 patients with combined hypertension and/or diabetes, the fever and cough time of the fapilave group was significantly shorter than in the Abidor group, but there was no statistical difference in the proportion of patients receiving assisted oxygen therapy or noninvasive mechanical ventilation in both groups.
safety, the most likely adverse events include abnormal liver function test (LFT), psychopath response, digestive tract response, and elevated helactic acid, specific data can be found in the following table: Source: medRxiv Based on these results, researchers believe that in common COVID-19 patients, fapilav can be considered as the preferred treatment, because it has a high 7-day clinical recovery rate, in addition to some anti-viral adverse reactions, but also to reduce the incidence of fever, cough.
, however, the researchers also stressed that the trial has some limitations.
first, the control group has difficulty in drug selection, and there are no effective antiviral drugs for COVID-19 that have been validated by clinical trials.
the drugs recommended in the new Coronavirus Pneumonia Clinic (Trial Version 6) are also being tested for safety and efficacy in clinical studies.
chose Abidor because the drug was widely used by doctors in china in response to the COVID-19 outbreak.
, due to the limitations of the observation period, there is a lack of safety and effectiveness judgment for up to 1 month.
, there is a lack of evidence tracking of next month's recurrences, including nucleic acid testing for transcurrent, relapse and coughing, in patients discharged from the hospital with negative nucleic acid tests and normal CT imaging of the lungs.
third, positive nucleic acid testing is not included in the inclusion criteria.
fourth, the imbalance in the proportion of critically ill patients in the two groups (18 critically ill patients in the Fabiravir group and 9 critically ill patients in the Abidor group) had an important effect on the main and secondary results.
Special Note: According to medRxiv's statement, these medical advances published on the platform have not been peer-reviewed and are not yet evaluated and should not be used to guide clinical practice.
related research: s1. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) (Source: Nature Reviews Drug Discovery) (2) Remdesivir and chloroquine effectively inhibit the recentoly emerged noveled novelvirus (2019-nCoV) in vitro (Source: Cell Research) 4 days to clear the virus, good tolerance for safety (Source: Pharma Rubik's Cube) 2 s Cop: What is Abidoor who was included in the new coronavirus pneumonia diagnosis and treatment programme (Source: BambooHotline.com) 3? Notice on the issuance of a new coronavirus pneumonia diagnosis and treatment programme (trial version 6) (Source: Chinese government.com)